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An antigen-delivery system based on hybrid virus-like particles (VLPs) formed by the self-assembly of the capsid VP2
protein of canine parvovirus (CPV) and expressing foreign peptides was investigated. In this report, we have studied the
effects of inserting the poliovirus C3:B epitope in the four loops and the C terminus of the CPV VP2 on the particle structure
and immunogenicity. Epitope insertions in the four loops allowed the recovery of capsids in all of the mutants. However, only
insertions of the C3:B epitope in VP2 residue 225 of the loop 2 were able to elicit a significant anti-peptide antibody response,
but not poliovirus-neutralizing antibodies, probably because residue 225 is located in an small depression of the surface. To
fine modulate the insertion site in loop 2, a cassette-mutagenesis was carried out to insert the epitope in adjacent positions
226, 227, and 228. The epitope C3:B inserted into these positions was well recognized by the specific monoclonal antibody
C3 by immunoelectron microscopy. BALB/c mice immunized with these chimeric C3:B CPV:VLPs were able to elicit an strong
neutralizing antibody response (.3 log10 units) against poliovirus type 1 (Mahoney strain). Therefore, minor displacements
in the insertion place cause dramatic changes in the accessibility of the epitope and the induction of antibody responses.
© 1999 Academic Press
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mINTRODUCTION
Canine parvovirus (CPV) belongs to the feline parvo-
irus subgroup of the parvovirus genus. It causes an
nteric disease in puppies, being lethal in the most
evere cases. Parvoviruses have a single-stranded DNA
enome encapsidated in a T 5 1 (60 subunits) icosahe-
ral capsid, 25 nm in diameter (Cotmore and Tattersal,
987; Paradiso et al., 1982). The capsid is formed mainly
y a major structural protein called VP2. The structure of
P2 consists of an eight-stranded antiparallel b-barrel
otif with large insertions between the b-strands called
oops. For the feline parvoviruses, the loops between the
and C (loop 1), E and F (loop 2), and G and H (loops 3
nd 4) b-strands contain 36, 74, and 223 amino acids,
espectively (Tsao et al., 1991). The four loops make up
uch of the surface of the virus capsid and comprised
64 of the 547 residues resolved in the VP2 structure,
ith loops 3 and 4 forming the bulk of the spikes that
xtend 22 Å radially outwards around the threefold axes.
he spikes contain many of the virus B-cell epitopes,
eing the immunodominant domains of the capsid
Strassheim et al., 1994). Mutations that affect canine and
eline host ranges, uncoating, and erythrocyte binding
ctivities are also found on regions of the threefold spike
1 To whom reprint requests should be addressed. Fax: 34 91
f087598. E-mail: icasal@ingenasa.es.
89Chang et al., 1992; Tresnan et al., 1995). Other antigenic
egions were found at the N- and C-termini of the VP2
ubunits (Langeveld et al., 1993; Lopez de Turiso et al.,
991).
Recently, we have described the production of CPV
mpty particles consisting only of VP2, prepared in a
aculovirus expression system (Lopez de Turiso et al.,
992). The use of deletion mutants allowed to define
ome essential domains in porcine parvovirus (PPV)
Sedlik et al., 1995) and CPV VP2 (Hurtado et al., 1996) for
he assembly of virus-like particles (VLPs). From these
tudies, we conclude: (i) the N terminus is probably the
est site for insertions, since insertions in this place do
ot alter the structure. However, the N terminus is com-
letely hidden inside the capsid, being unaccessible to
ntibodies (Corte´s et al., 1993; Sedlik et al., 1995). (ii)
eletions in loops 1, 3, 4, and the C terminus, avoid the
orrect assembly of the capsids, while mutants with
eletions in loop 2 were able to assemble into regular
LPs (Hurtado et al., 1996). Thus, most of the exposed
esidues are involved in critical interactions necessary
or the assembly of the particle. On the other hand,
revious studies on the virus immunogenicity suggest
hat the loops seem to be the most suitable sites for the
nsertion of epitopes in order to use the CPV particles as
arrier molecules for antigen delivery and the develop-
ent of subunit vaccines. So, residues 300–301 in loop 3orm part of neutralizing site B in the threefold spike
0042-6822/99 $30.00
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90 RUEDA ET AL.Strassheim et al., 1994) and Asn 93 in loop 1 is involved
n the recognition of a MAb able to differentiate CPV from
eline panleukopenia virus (FPLV) (Chang et al., 1992).
In this report, we have used structural and antigenic
ata for a rational approach to the construction of inser-
ion mutants in the surface of CPV capsids. Poliovirus
3:B epitope comprising VP1 residues 93–104 was used
s a model (Horaud et al., 1987; Van der Werf et al., 1983).
t was inserted near the tips of the loops, taking advan-
age of the presence of unique restriction sites in these
egions. The C terminus was also investigated, since we
ave found previously some antigenic sites associated
o this position (Langeveld et al., 1993). Despite the 3D
nformation, an optimization study was necessary to find
n appropriate insertion site in the surface of the capsid.
RESULTS
nsertion strategies in the loops and C terminus
f CPV VP2
Selection of insertion sites in the loops was based on
he presence of unique restriction sites close to the tips
f the loops. This approach was possible in the case of
oops 1, 2, and 4, which contain restriction sites HpaI,
peI, and MunI, respectively. In the case of loop 3, a new
frI site was engineered by site-directed mutagenesis.
wo strategies were used for the reconstruction of the
3:B polio epitope. The epitope sequence could be re-
FIG. 1. Oligonucleotides and amino acid sequences of the poliovirus
oops and the C terminus. Amino acids in bold constitute the epitope
ndicated.enerated by either two complementary oligonucleo- pides or two oligonucleotides overlapping in eight nucle-
tides, which were amplified by PCR and, finally, di-
ested with the appropriate restriction enzyme. As
ndicated in Fig. 1, insertions in loops 2, 3, and C-termi-
us create a repetition of 2 residues at each end of the
pitope and loop 4 mutant duplicates 1 residue. The
utated genes were subcloned in the pAcYM1 baculo-
irus transfer vector and used to generate the recombi-
ant baculoviruses. They were called AcCPV1-C3:B, Ac-
PV2-C3:B, AcCPV3-C3:B, and AcCPV4-C3:B for the
oops 1, 2, 3, and 4, respectively, and AcCPVC-C3:B for
he C terminus.
haracterization of the VP2 insertion mutants
To analyze the expression of the VP2 chimeras, Sf9
ells were infected with each recombinant baculovirus at
multiplicity of infection of 3 PFU per cell. Cells were
ollected at 72 hpi and the total proteins were analyzed
y SDS–PAGE and immunoblotting (Fig. 2). All recombi-
ant baculoviruses expressed the expected VP2 mutant
rotein as detected with the monoclonal antibody (MAb)
C9 specific for CPV VP2 (Fig. 2). The levels of expres-
ion detected after Coomassie blue staining were similar
or all of them, except for the mutant CPVC-C3B in the C
erminus. This mutant showed a lower expression and a
ajor degradation as confirmed by the presence of
bundant low molecular weight extra bands in the pro-
ein preparations (Fig. 2). The presence and correct ex-
pitope used for insertions in the CPV VP2 capsid gene at the different
ce. Duplicated residues are marked with a dot. Restriction sites areC3:B e
sequenression of the C3:B epitope in all the insertion mutants
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91CPV VLPs AS ANTIGEN DELIVERY SYSTEMas confirmed by immunoblotting analysis with the MAb
3 (data not shown).
To determine whether the VP2 insertion mutants were
ble to form VLPs, lysates containing equal amounts of
nfected Sf9 cells were analyzed by ultracentrifugation in
sCl gradients and then by electron microscopy. An
palescent band was observed in the mutants CPV1-
3B, CPV2-C3B, CPV3-C3B, and CPV4-C3B, indicating
he presence of particles. Mutant CPVC-C3B was not
ble to band in the CsCl-gradients. Electron microscopy
nalyses confirmed the presence of regular VLPs in the
our mutants of the loops, but not in the carboxy-terminal
utant. However, loop 3 insertions produced a lower
umber of particles and the morphology of the particles
as not well preserved.
ccessibility of the epitope on the surface
f the capsids
The accessibility of the C3:B epitope on the surface of
he capsids was first determined by indirect ELISA, using
he VP2 mutants as coating antigens and the MAb C3 for
etection. The wild type (wt) VP2 and the C3:B peptide
ere used as controls. The results are shown in Fig. 3.
nsertions in loop 2 gave the highest values of absor-
ance, indicating a better recognition by the MAb C3.
oops 3 and 4 showed some accessibility as they
ielded absorbance values well above background lev-
ls. The other two mutants showed a weak or negligible
eactivity with the MAb C3. It is noteworthy the low
ccessibility of the epitope in loop 1, in contrast with the
ood morphology of the capsids.
FIG. 2. Expression and formation of empty capsids by the VP2 ins
ecombinant baculovirus at a moi of 3 PFU per cell. Extracts of the cell
rom the cytoplasmic fractions after cell lysis was analyzed by Western
eroxidase-conjugated goat anti-mouse immunoglobulin G. The positio
olecular weight markers are indicated in both cases on the left.To check the accessibility of the epitope in native conditions, mutant CPV2-C3B particles were labeled with
mmunogold using either the MAb C3 or specific poly-
lonal antibodies (data not shown). None of the antibod-
es reacted with the particles, despite repeated attempts
n different conditions. This result suggests that the ac-
essibility is probably restricted to large probes as im-
unoglobulins in native conditions. One reason for the
iscrepancy could be the partial denaturation of the
ntigen, and thereby exposure of otherwise hidden
pitopes, by direct coating in ELISA plates.
mmunogenicity of the VP2 insertion mutants
The ability of the chimeric proteins to induce an anti-
ody response against the C3:B epitope was tested by
mmunizing BALB/c mice. The antibody production was
valuated by indirect ELISA, immunoblotting, and in vitro
eutralization experiments. The results of the peptide-
pecific ELISA are shown in Fig. 4. The four mutants of
he loops developed high antibody titers (104–105)
gainst CPV VP2, indicating an efficient immunization of
he mice against the particulate antigen. However, only
hose sera from mice immunized with the loop 2 mutant
eveloped C3:B-specific antibodies, although in low titer
103). The rest of the mutants failed to induce epitope-
pecific antibodies, indicating the poor immunogenicity
f the epitope at these positions.
The C3:B-specificity of the antibodies induced by
PV2-C3B was confirmed by immunoblotting analysis
sing chimeric porcine parvovirus (PPV) particles con-
aining the same epitope (Sedlik et al., 1995) or purified
oliovirus Mahoney strain (data not shown). In both
mutants in insect cells. S. frugiperda cells were infected with each
harvested and prepared as described above. The material recovered
ith MAb 3C9 for CPV VP2 detection. The reaction was developed with
e different mutants are indicated on the top. VP2, wild-type CPV VP2.ertion
s were
blot w
ns of thases, a specific recognition of the protein band was
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92 RUEDA ET AL.btained with the antisera. To analyze the biological
ctivity of these antibodies, an in vitro protection assay
as carried out. Despite the results showed a very weak
eutralizing activity of the antibodies (data not shown),
oop 2 seemed to be the most appropriate place for
nsertion of foreign B-cell epitopes, since no major
hanges in the structure were observed.
FIG. 3. Accessibility of the C3:B epitope in chimeric CPV-C3B. End
PV1-C3B, CPV2-C3B, CPV3-C3B, CPV4-C3B, and CPVC-C3B. Peptide
FIG. 4. Immunogenicity of CPV-C3B chimeras in mouse. Pools of ser
PV-C3:B chimeras were made at day 51 postimmunization and teste
escribed above. Endpoint ELISA titers of the mouse antisera are repre
rebleeding sera as a negative control.ptimization of the insertion site in loop 2
In an attempt to improve the accessibility and immuno-
enicity of the epitope and to remove the duplication of two
esidues at each end, new mutants containing the C3:B
pitope were constructed by “cassette mutagenesis” in VP2
ositions 226, 227 and 228 of the loop 2. Sf9 cells were
LISA titers of the MAb C3 against purified preparations of CPV VP2,
as used as a control.
different groups of mice immunized with purified preparations of the
nst the C3:B peptide according to the same indirect ELISA protocol
starting at 1/200 dilution. MAb C3 was used as a positive control andpoint Ea of the
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93CPV VLPs AS ANTIGEN DELIVERY SYSTEMnfected with the recombinant baculoviruses expressing
he respective mutants and the expression of VP2 chimeras
as analyzed by SDS–PAGE and immunoblotting. The
hree mutants were expressed at high levels as demon-
trated by SDS–PAGE analysis (Fig. 5A) and showed a
orrect expression of the C3:B epitope as determined by
mmunoblotting analysis with the MAb C3 (Fig. 5B). The
ew mutants were able to form VLPs as determined by
sCl-gradient analysis. Electron microscopy analysis con-
irmed the presence of abundant VLPs in each mutant, with
he expected size and appropriate morphology.
To analyze the external location of the C3:B epitope on
he surface of the VLPs, we used two assays. First,
olloidal-gold labeling with the MAb C3:B was carried
ut by immunoelectron microscopy (Fig. 6). Mutants
PV226-C3B and CPV227-C3B were both well labeled
ith the MAb C3. In contrast, the VP2 particles of the
utant CPV228-C3B were poorly labeled, suggesting a
ower accessibility of the epitope in this position. As
xpected, wt VP2 particles stained with the MAb C3
howed no labelling. Second, capsids purified by salt
recipitation were used for an indirect ELISA. The results
re shown in Fig. 7. There was an excellent agreement
etween the ELISA results and the immunoelectron mi-
roscopy results. VP2 mutants 226 and 227 were much
etter recognized by MAb C3 in ELISA than mutant 228.
n summary, all these results suggest large differences in
ccessibility of the epitope by minor displacements.
mmunogenicity of CPV VP2 mutants 226, 227,
nd 228 containing the C3:B epitope
To evaluate the immunogenic properties of these new
FIG. 5. Expression and formation of empty capsids by CPV VP2 mutan
nfected with each recombinant baculovirus at a moi of 3 PFU per ce
himeric VP2 preparations were loaded on a 9% SDS–PAGE and stain
P) (A). The presence of the C3:B epitope was confirmed by immunoblo
he top. VP2, wild-type CPV VP2. Molecular weight markers are indicaybrid particles, we immunized BALB/c mice with the ahree CPV mutants containing the C3:B epitope in posi-
ions 226, 227, and 228, either in incomplete Freund’s
djuvant (IFA) or in phosphate-buffered saline (PBS). The
esults of the anti-CPV and anti-C3:B peptide ELISA titers
re shown in Table 1. All mice developed antibodies that
ecognized the peptide as well as CPV. The antibody
iters of mice immunized with the particles in IFA were
lways 4 to 10 times higher than those immunized with-
ut adjuvant. Moreover, these antisera exhibited a high
iter of poliovirus-neutralizing antibodies (Table 1). In all
he mutants, some individual mouse neutralization titers
ere very high, more than 3 log10 units. Surprisingly,
utant CPV228-C3B elicited the highest level of re-
ponse against the C3:B peptide (4 3 105). Mice immu-
ized without adjuvant gave no neutralization titer, ex-
ept for mutant 228, which showed a low neutralizing
esponse (1.6 log10 units).
DISCUSSION
The use of genetically engineered particles as carriers
or polypeptides and their use as subunit vaccines and
elivery systems has raised a considerable interest dur-
ng the last decade due to their inherent properties such
s multimeric antigens, spatially uniform distribution,
articulate structure, etc., which are essential for an
fficient recognition by the immune system. The CPV
LPs are potentially an excellent candidate for antigen
elivery. Indeed, they posses several important advan-
ages: Namely, (i) VLPs are composed by a single protein
VP2), (ii) VLPs, as natural virions, are tremendously sta-
le, (iii) VLPs are highly immunogenic (Sedlik et al., 1995,
997), and (iv) they can be purified in large amounts with
227, and 228 insertion mutants in insect cells. S. frugiperda cells were
acts of the cells were harvested and prepared as described above.
Coomassie blue before (ST) or after ammonium sulfate precipitation
ith MAb C3 (B). The positions of the different mutants are indicated on
the left.ts 226,
ll. Extr
ed with
tting wrelatively simple procedure (Lopez de Turiso et al.,
1
m
d
(
P
u
c
i
t
v
(
l
e
e
C
m
f
m
m ranyl a
94 RUEDA ET AL.992; Hurtado et al., 1996). In fact, contamination by
onomers, trimers, or pentamers should be marginal as
emonstrated previously by banding in CsCl gradients
Hurtado et al., 1996).
From our previous studies with deletion mutants of
PV and CPV VLPs, we conclude that it is probably
nwise to delete any CPV-specific sequence during the
onstruction of the chimeras (Hurtado et al., 1996). Sim-
lar results have been described for other chimeric par-
FIG. 6. Electron microscopy. Immunogold labeling with the MAb C3
utants 226, 227, and 228. Particles were negatively stained with 2% uicles, as, for instance, those derived from human parvo- airus B19 (Brown et al., 1994) and cowpea mosaic virus
CPMV) (Porta et al., 1994). In this report, we have ana-
yzed the potential of purified CPV VLPs to carry foreign
pitopes in the different loops or in the C terminus and to
licit neutralizing antibodies recognizing the epitope
3:B of poliovirus type 1. In contrast to the deletion
utants, all the insertions in the loops gave place to the
ormation of particles, suggesting that the particle is
ore flexible to accommodate foreign sequences, prob-
onium sulfate-purified chimeric or empty capsids formed by CPV VP2
cetate.of ammbly because no critical residues for the structure of the
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95CPV VLPs AS ANTIGEN DELIVERY SYSTEMapsid are removed. However, there were considerable
ifferences in the number of particles obtained for each
utant and in the stability of the particles. These two
arameters, number of particles and stability, showed a
irect correlation. CPV VP2 modified in the C terminus
as quickly degraded, presumably because it was un-
ble to assemble. Loop 3 and 4 mutants which yielded a
ow number of particles were also less stable VP2 pro-
eins as shown by SDS–PAGE analysis after storage at
°C (data not shown). These results suggest that forma-
ion of particles may depend on, at least, two sequential
actors: (i) the expression of large amounts of protein in
concentration sufficient to allow assembly, as previ-
usly demonstrated for other virus-assembly processes
Araki et al., 1990; Fu et al., 1996) and (ii) a proper
ssembly process is required, otherwise the VP2 mutant
FIG. 7. Accessibility of the C3:B epitope in CPV VP2 mutants 226
reparations of CPV VP2, CPV226-C3B, CPV227-C3B, and CPV228-C3B
T
Antibody Responses Induced in Vivo b
ELISAa
anti-CPV
utant IFA PBS
PV226-C3B 2 3 105 5 3 104
PV227-C3B 2 3 105 5 3 104
PV228-C3B 2 3 105 5 3 104
rebleeding — —
a Mouse sera were obtained at day 50 postimmunization. ELISA titer is
hat gave an absorbance greater than the cut-off value (cut-off value w
b Mouse sera were obtained at day 50 postimmunization. The neutra
iving 50% plaque reduction in two different experiments.c — Below detection limit.ill be degraded. Thus, although all the VP2 mutants
eem to be expressed at the same level, its ability to
elf-assemble is probably determining its lifespan.
The lower number of particles observed in loop 3 and
mutants would imply that the epitopes are situated in
ites interfering with the correct assembly of VP2 parti-
les, probably because they are involved in critical sub-
nit–subunit interactions, formation of salt bridges and
ydrogen bonds. Residues 300 and 301 of loop 3 form
art of the region called shoulder, which is composed of
ive polypeptide loops from three different capsid pro-
eins (Tsao et al., 1991). Formation of salt bridges in the
houlder region was predicted to stabilize the capsid
Llamas-Saiz et al., 1996). Residues 300 and 301 also
orm part of neutralizing site B (Strassheim et al., 1994;
ikoff et al., 1994). Moreover, changes in residues 299,
nd 228 particles. Endpoint titration of the MAb C3 against purified
was carried out as described above.
mbinant CPV-C3:B Chimeric Capsids
Neutralization titerbanti-C3:B
PBS IFA PBS
2 3 104 2.5 6 0.4 —c
2 3 104 2.7 6 0.4 —
2 3 104 2.6 6 0.5 1.6 6 0.2
— — —
ean of individual titers and is expressed as the reciprocal of the dilution
en as the mean 6 (23 SD of the negative control).
titers are computed as the reciprocals of the dilutions of sera (log10), 227, aABLE 1
y Reco
IFA
105
2 3 105
4 3 105
—
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96 RUEDA ET AL.00, or 301 caused the virus to lose the ability to infect
anine cells (Parker and Parrish, 1997). It has been hy-
othesized that the conformation of the shoulder region
n the capsid of CPV is critical for infection of canine cells
nd that salt bridges within this region may be important
or both conformation and stability (Parker and Parrish,
997). In the case of loop 4, changes in residues 435–437
ay distort hydrogen bonding between threefold related
ubunits (Wu and Rossmann, 1993).
Immunization of BALB/c mice with all four loop mu-
ants revealed that only CPV2-C3B, the mutant in loop 2,
eveloped an immune response against the inserted
3:B epitope. However, these sera did not show neutral-
zing activity against poliovirus, suggesting that the pep-
ide accessibility was not enough to elicit high titer an-
isera and further changes were necessary for a better
ntigen presentation. A reason for the poor immunoge-
icity of this position could be that residue 225, as
esidue 93 in loop 1, is located within a slight depression
f the surface, not accessible to large probes (Chapman
nd Rossmann, 1993). The same situation applies to
esidues 302–304 of loop 3 and 436–437 of loop 4.
herefore, at least one of the initially selected residues of
ach loop was not fully accessible. This circumstance,
orced by the use of natural restriction sites, may explain
hy the mutants showed a low accessibility and immu-
ogenicity.
To overcome this limitation, we decided to use a con-
inuous stretch of exposed residues in the loop 2 of VP2.
he region from Ser-226 to Thr-230 in loop 2 contains
ne of the longest continuous stretches of accessible
esidues in the VP2 chain (Chapman and Rossmann,
993). Thus, we carried out a systematic mutagenesis of
oop 2 residues avoiding sequence duplications at either
ide of the inserts, which have been troublesome in
ther chimeras (Porta et al., 1994). After mice immuniza-
ion, we found that the results of accessibility and immu-
ogenicity of the new chimeras improved dramatically. It
s remarkable that after removing the flanking repeats, a
inor displacement, from before position 225 to position
26, causes a striking effect in accessibility and antigen
resentation. These results suggest that a similar ap-
roach could be repeated for the other loops. Residues
8–91 in loop 1, residues 296–302 in loop 3, and residues
19–426 in loop 4, could be investigated for accessibility.
till, the effect of insertions in these loops on the struc-
ure of the capsid remains problematic. In fact, and
ccording to our previous data (Hurtado et al., 1996),
odifications in these loops seem to be more prone to
ause a destabilizing effect than modifications on the
oop 2.
A puzzling observation relates to the results obtained
ith mutant 228. Despite the apparently lower accessi-
ility of the epitope as compared to 226 and 227, the
mmunogenicity of the epitope in this position seems to
e superior. However, MAb C3:B, used for detecting the spitope, may recognize it in a particular orientation,
hich is not necessarily the best orientation for immuni-
ation. Regarding the use of adjuvants, although PBS is
ufficient to elicit an antibody response against the pu-
ified CPV VLPs, it is not enough to induce high neutral-
zation titers against poliovirus. It seems reasonable that
ince the epitope makes only about 2% of the total
ntigen content, some adjuvant needs to be included in
he preparations for enhancing the immunogenicity. In
ny case, the effective epitope content of each vaccinal
ose remains extraordinarily low (;1 mg).
In conclusion, our results confirm the general applica-
ility of the three rules proposed for the construction of
irus-based chimeras (Lomonosoff and Johnson, 1995):
i) No wild-type viral sequences should be removed, (ii)
equence duplications either side of an insert should be
voided, and (iii) the site of insertion should be opti-
ized. The application of these rules to CPV VLPs has
llowed us to obtain chimeric particles carrying inserted
olypeptides that are structurally stable and highly im-
unogenic. Obviously, this same approach could also be
sed for generating live parvovirus chimeras. Next step
ill be to determine the length of the largest insert that
an be stably expressed on the loop 2 of the surface of
PV. The results of our study open the possibility of
nserting simultaneously B and T cell epitopes in the loop
and the N terminus, respectively. The combination of
ifferent types of epitopes (B, CD41, and CD81) in
ifferent positions of the parvovirus particles opens the
ay to the development of highly efficient vaccines, able
o stimulate at the same time the different branches of
he immune system.
MATERIALS AND METHODS
Viruses and cells. Spodoptera frugiperda (Sf9) cells
ere grown and maintained as described before (Sum-
ers and Smith, 1987). Autographa californica nuclear
olyhedrosis virus recombinant derivatives were ob-
ained by lipofectine cotransfection, plaque-purified, and
ropagated as previously described (Hurtado et al.,
996).
Poliovirus type 1 (Mahoney strain) was used for the in
itro protection assays on BGM cells. They were a kind
ift of Dr. G. Trallero (CNM, Inst. Salud Carlos III, Maja-
ahonda, Spain).
Insertion of epitopes in the CPV VP2 gene and con-
truction of recombinant transfer vectors. Poliovirus
pitope C3:B was inserted in the four loops and the
arboxy end of the VP2 protein. In every case, an internal
estriction site NheI (underlined in the oligonucleotide
equence) was engineered in the epitope sequence to
acilitate the screening of the recombinant clones con-
aining the insert. The oligonucleotides used for the in-
ertions in the different loops are shown in Table 2.
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97CPV VLPs AS ANTIGEN DELIVERY SYSTEMligonucleotides were purchased from Pharmacia Bio-
ech (Spain).
Insertions in loop 1 were made using the HpaI site (nt
74–279 of the VP2 sequence, corresponding to aa 92–
3). Oligonucleotides were treated with T4 polinucleotide
inase and then allowed to self-anneal at 70°C for 15 min
nd ligated directly into HpaI-digested alkaline phos-
hatase-treated pCPV13 and transformed into Esche-
ichia coli DH5 cells. The recombinant clones were an-
lyzed for the presence of the insert by enzymatic diges-
ion with NheI. For insertions in loop 2, two overlapping
ligonucleotides CPV2.C3 (1) and (2) of 28 and 32 nt,
espectively, were designed in order to regenerate by
CR the C3:B sequence plus two flanking SpeI restriction
ites, which results in the repetition of two residues at
ach side of the epitope. For PCR, 800 ng of each primer
ere denatured for 3 min at 94°C. The samples were
hen subjected to 25 rounds of amplification under the
ollowing conditions: 93°C for 1 min, annealing at 37°C
or 1 min, and extension at 72°C for 2 min. A final
olishing step was carried out at 72°C for 7 min. The
eactions were done with Vent DNA polymerase (1 unit)
New England Biolabs). The PCR product was digested
ith SpeI and subcloned into SpeI-digested pCPV13 (nt
74–679, aa 225–226). For insertions in loop 3, two com-
lementary oligonucleotides containing flanking BfrI
ites were allowed to self-anneal and ligated into BfrI-
igested pCPV22 (nt 906–911, aa 302–304) (Hurtado et
l., 1996). In order to maintain the open reading frame, it
as necessary to introduce two additional nucleotides
GC) at the 59 end of the oligonucleotide CPV3.C3 (1).
hus, a new amino acid is inserted and two residues are
epeated at each end. For insertions in loop 4, the unique
estriction site MunI (nt 1304–1309, aa 435–437) was
sed. The oligonucleotides CPV4.C3 (1) and (2) were
elf-annealed and ligated into MunI-digested pCPV13. A
unI site was regenerated at the 59 end of the insertion,
hich results in one residue repetition at each end.
To make insertions in the C terminus of VP2, a site-
irected mutagenesis in pCPV13 was first carried out by
CR to create a unique BfrI restriction site immediately
T
Oligonucleotides Used for
Oligonucleotides Forward primer
CPV1.C3 GACAACCCCGCTAGCACCACCAACAAGGA
CPV2.C3 TGGAACTAGTGACAACCCCGCTAGCACC
CPV3.C3 TTAAGCGACAACCCCGCTAGCACCACCAAC
CPV4.C3 AATTGACACCCCCGCTAGCACCACCAACAA
CPV226.C3 GGAACTAGTGACAACCCCGCTAGCACCAC
CPV227.C3 GGAACTAGTGGCGACAACCCCGCTAGC
CPV228.C3 GGAACTAGTGGCACAGACAACCCCGCTAG
Note. The restriction sites used in the screening of the mutants areefore the termination codon of the VP2 gene. The PCR dutagenesis was done by using the oligonucleotides
PV1N(1) (nt 1–24) ATGAGTGATGGAGCAGTTCAACCA
nd CPV.CBfrI(2) (nt 1736–1761) AGTATGTTAACTTA-
GTTTCTAGG (BfrI cloning site is underlined). For the
CR, 100 ng of pCPV13 DNA were mixed with 800 ng of
rimers and denatured for 3 min at 94°C. The reaction
onditions were as described above, except that the
nnealing was realized at 40°C. The PCR product was
reated with phenol-chloroform and precipitated with eth-
nol. Then, the product was treated with T4 polynucle-
tide kinase (10 units), ligated into SmaI-digested
MTL25 and transformed into E. coli XL1-blue. After
hecking the sequence, the new plasmid was called
CPV24. The insertion in this position, was carried out
ith the same oligonucleotides CPV3.C3 (1) and (2),
nd procedures used for the loop 3. In all cases, the
orrect sequence of the insertions was checked by se-
uencing with the dideoxynucleotide technique (Sanger
t al., 1977).
Cassette mutagenesis in loop 2. A cassette mutagen-
sis was carried out in order to prepare consecutive
utants along loop 2. To this end, a new BstBI restriction
ite was created in nt 687–692 by PCR mutagenesis with
he oligonucleotides CPV.BstBI (ACTGGAACTAGTGGCA-
ACCTTCGAATATA) (BstBI sequence is underlined) and
PVC.BfrI (2). The PCR product was digested with SpeI
lus MunI and the resulting fragment was used to re-
lace the original fragment in clone pCPV13. The new
onstruction was called pCPV27.
VP2 positions 226, 227, and 228 were selected for
nsertion. To carry out the cassette mutagenesis, the
ligonucleotides shown in Table 2 were requested. The
ligonucleotides were annealed and extended by PCR
conditions as above). PCR products and plasmid
CPV27 were digested with SpeI and BstBI for subclon-
ng and, after ligation, transformed into E. coli by elec-
roporation. New constructions were called pCPV226-
3B, pCPV227-C3B, and pCPV228-C3B.
Preparation of recombinant baculoviruses. All the in-
ertion mutants were rescued from the respective plas-
ids by BamHI digestion and subcloned into BamHI-
nstruction of the Mutants
Reverse primer
TTTGTCCTTGTTGGTGGTGCTAGCGGGGTTGTC
GCCACTAGTTTTGTCCTTGTTGGTGGTGCTAG
ACAAA TTAATTTGTCCTTGTTGGTGGTGCTAGCGGGGTTGTCGC
AA AATTTTGTCCTTGTTGGTGGTGCTAGCGGGGGTGTC
AGG ATATTCGAAGGTGTGCCTTTGTCCTTGTT
ATATTCGAAGGTGTTTTGTCCTTGTTGGTGGTGCTAGCG
ATATTCGAAGGTTTGTCCTTGTTGGTGGTGCTAGCG
ined.ABLE 2
the Co
CAAA
AAGG
GGAC
CAACA
Cigested pAcYM1 baculovirus transfer vector (Matsuura
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98 RUEDA ET AL.t al., 1987). Selection of mutants and preparation of
ecombinant baculoviruses was made as described be-
ore (Hurtado et al., 1996). The recombinant baculovi-
uses were plaque-purified and then high-titer virus
tocks were obtained.
Characterization and purification of chimeric particles.
. frugiperda cells were infected with the recombinant
aculoviruses at a multiplicity of infection of 3 PFU per
ell, and extracts of the cells were recovered at 72 h
ostinfection. The chimeric proteins were characterized
y SDS–PAGE and immunoblotting analysis as de-
cribed before (Hurtado et al., 1996). MAb 3C9, specific
or the N terminus of CPV VP2 (Lopez de Turiso et al.,
991; Langeveld et al., 1993), was used for the detection
f chimeric VP2. The ability of the mutants to assemble
nto particles was determined by ultracentrifugation in
sCl gradients and electron microscopy analysis as de-
cribed earlier (Hurtado et al., 1996).
For purification of VP2 chimeras, S. frugiperda cells
ere infected with each recombinant baculovirus at a
ultiplicity of infection of 3 PFU per cell. Cells were
ollected at 72 h postinfection, washed with PBS, and
ysed in 25 mM sodium bicarbonate solution. After re-
oving the cell pellet by low-speed centrifugation, puri-
ied preparations of VP2 were obtained by 20% ammo-
ium sulfate precipitation. The pellet was resuspended
nd dialysed overnight against PBS. Since not all the
reparations showed the same stability, all the antigens
ere prepared immediately before immunization.
ELISA. To analyze the antibody response and to detect
he accessibility of the epitope C3:B at the surface of the
utant particles, an indirect ELISA was carried out.
riefly, 96-well microtiter plates (Nunc) were coated with
ither 0.5 mg of C3:B peptide (Genosys.UK) or 1 mg of
P2 mutant, respectively, in 100 ml of PBS, overnight at
°C. Then plates were incubated with twofold serial
ilutions of the MAb C3 (a kind gift of Dr. R. Crainic,
asteur Institute, France) in PBS–0.05% Tween 20 for 1 h
t 37°C. After washing, plates were incubated with per-
xidase-conjugated goat anti-mouse IgG (1/4000 in
BS–0.05% Tween 20) for 1 h at 27°C. Reaction was
etected by adding ABTS (2,29 azino-di[ethyl-benzothia-
oline] sulfonic acid) as substrate and stopped by the
ddition of 1% SDS. The optical density of the samples
as determined at 405 nm in an ELISA reader (Bio-Tek
nstruments, U.S.A.).
Immunization of mice. Two types of immunization ex-
eriments were carried out. For mutants containing di-
ect insertions in the loops, groups of five BALB/c mice
eceived four injections of 50 mg of protein per mouse
ntraperitoneally at days 0, 15, 30, and 45. The first two
oses were given in complete Freund’s adjuvant (CFA)
nd IFA (Sigma), respectively, and then in PBS. Mice
ere bled at days 25, 41, and 51 for the serological
nalysis.For the different mutants of loop 2, groups of threeice were immunized with three doses (20, 50, and 50
g) of protein per mouse at days 0, 21, and 42. For each
ntigen, one group was immunized with IFA and the
ther group with PBS. Mice were bled at days 0, 28, and
0. Sera obtained at day 50 were used for the serological
nd neutralization assays.
In vitro neutralization assays. BGM cells were cultured
n M6 plates (Costar, U.S.A.) at 4 3 105 cells/well. Inac-
ivated mouse sera were diluted in DMEM (GibcoBRL)
nd mixed with 200 PFU of poliovirus (Mahoney strain)
or 2 h at 26°C and then overnight at 4°C. Next day, BGM
ells were infected with 200 ml of the mixture for 30 min
t 37°C. Then medium was removed and the cells were
verlayed with a mixture of 2% agarose and 2 3 DMEM
or 24 h. For counting plaques, cells were stained with
rystal violet as previously described (Lopez de Turiso et
l., 1991). The reciprocals of the dilutions of serum sam-
les giving 50% plaque reduction in two different exper-
ments were accounted as the neutralization titers ex-
ressed in log10.
Immunoelectron microscopy. Preparation of colloidal
old was performed according to Slot and Geuze (1985).
o the surface of the newly prepared gold sols (AuT3)
as coupled goat anti-mouse immunoglobulin (DAKO,
enmark). The labeling was performed by first adsorbing
he VP2 chimeras to carbon-coated formvar grids for 5
in and then the grid was washed twice on droplets of
SA-TS buffer (4% BSA in 10 mM Tris–HCl, pH 7.4, 15 mM
aCl) and placed on droplets of MAb C3 diluted 1:450 in
SA-TS and placed on a droplet of the colloidal-gold
abelled-antibody diluted 1:5 in BSA-TS and incubated for
0 min. Then the grids were washed briefly once in
SA-TS and once in water before staining with 2% uranyl
cetate for 30 s and then air-dried before examination by
ransmission electron microscopy.
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